Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novo Nordisk A/S
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Efficacy and safety of semaglutide once-weekly versus placebo as add on to SGLT-2i in subjects with type 2 diabetes mellitus
To compare the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodiumglucose co-transporter-2 inhibitor monotherapy or in combination with either metformin or sulfonylurea o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes
To confirm the effect of continuous subcutaneous insulin infusion (CSII) treatment with faster-acting insulin aspart in terms of glycaemic control by comparing it to CSII treatment with NovoRapid®, in...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Evaluation of safety following Immune Tolerance Induction treatment with turoctocog alfa in patients with haemophilia A following inhibitor development in NN7170-4213 trial
To evaluate safety of immune tolerance induction treatment with turoctocog alfa in patients who have developed neutralising antibodies against factor VIII after exposure to subcutaneous turoctocog alf...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A randomised, controlled, open label, multicentre, multinational, treat-to-target trial investigating the efficacy and safety of intensification with addition of bolus insulin aspart in subjects with type 2 diabetes inadequately controlled on basal insulin with or without oral anti-diabetic drugs: Step-wise addition versus complete basal-bolus therapy
The primary objective of this trial is to confirm efficacy of step-wise addition of bolus insulin in terms of glycaemic control assessed by change in HbA1c. This is done by comparing the difference in...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
The efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on GLP-1 receptor agonist and OAD therapy
To confirm superiority of insulin degludec/liraglutide versus unchanged glucagon-like peptide-1 (GLP-1) receptor agonist therapy in controlling glycaemia in insulin naïve subjects with type 2 diabetes...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A trial comparing NNC0123-0000-0338 in a tablet formulation and insulin glargine in subjects with type 2 diabetes currently treated with oral antidiabetic therapy
To compare the glycaemic control after 8 weeks of treatment with oral insulin 338 in a GIPET® I tablet formulation versus subcutaneous insulin glargine, when both are administered once daily in combin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A randomised, double-blind, placebo-controlled trial to assess safety, tolerability and pharmacokinetics of liraglutide in obese adolescent subjects aged 12 to 17 years
To assess the safety and tolerability of liraglutide at doses up to 3.0 mg in an obese adolescent population aged 12-17 years and Tanner stage 2-5
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A trial comparing stepwise insulin intensification of biphasic insulin aspart (BIAsp) 30 and basal-bolus therapy with insulin glargine and insulin aspart in insulin naïve type 2 diabetic patients inadequately controlled on oral anti-diabetic therapy
To compare the effect of intensification with BIAsp 30 versus intensification with basal bolus insulin analogues (insulin glargine and insulin aspart) on glycaemic control.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of treatment intensification 38týdenní studie srovnávající účinnost a bezpečnost inzulínu degludec / inzulínu aspart a inzulínu glargin + inzulínu aspart u subjektů s diabetem 2. typu na bazálním inzulínu s perorálními antidiabetiky či bez nich vyžadujících intenzifikaci léčby
To confirm the effect of insulin degludec/insulin aspart once daily versus insulin glargine once daily in combination with insulin aspart once daily in controlling glycaemia after 26 weeks in subjects...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A 16 week randomised, open labelled, 3-armed, parallel group, treat-to-target trial comparing twice daily (BID) injections of SIAC 30 (B), SIAC 45 (B) and NovoMix® 30, all in combination with metformin in subjects with type 2 diabetes failing on OAD treatment
To assess glucose control with respect to HbA_1c after 16 weeks of treatment with SIAC 30 (B) or SIAC 45 (B) BID or NovoMix®30 BID, all in combination with metformin, in subjects with type 2 diabetes,...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
8
9
10
11
12
13
14
15
16
17
Suivant